JMP Securities Maintains Market Outperform on Arbutus Biopharma, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on Arbutus Biopharma (NASDAQ:ABUS) and raises the price target from $4 to $5.
August 02, 2024 | 5:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reaffirmed its Market Outperform rating on Arbutus Biopharma and increased the price target from $4 to $5, indicating confidence in the company's future performance.
The raised price target and maintained Market Outperform rating from JMP Securities suggest positive sentiment and confidence in Arbutus Biopharma's future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100